arrow
返回

Transmission matrix-based phase correction for optical systems

delete2022-09-30
delete3
PRE
AI
K
Kaige Liu
H
Hengkang Zhang
Z
Zeqi Liu
张
张彬 (Bin Zhang) *
X
Xing Fu
Q
Qiang Liu *
DOI:10.1364/OL.469051delete
delete原文链接
delete原文求助
delete分享
delete收藏
摘要

摘要

En 中文
The demands in fields such as biology and communications are driving the development of structured light. However, the optical modulation devices which play an important role in generating structured light, often introduce phase distor-tion. Additional phase correction is required to obtain more precise modulation capabilities. In this Letter, we propose a transmission matrix (TM)-based phase correction method. With the measured TM, which establishes a link between the spatial light modulator (SLM) panel and the far-field distribution of the output, we can obtain the phase modula-tion achieving the ideal focus. The spatial distribution of the phase distortion can be extracted from the conjugate of this phase distribution. In our experiment, the sharpness metric of the focus dropped to about half. We further verified the availability of this method by correcting the phase distortion of Laguerre-Gaussian (LG) fields. We believe our method provides a simple way to achieve precise phase correction, which will be of interest in aspects of wavefront shaping and optical tweezers. (c) 2022 Optica Publishing Group
Keyword:
WAVE-FRONT CORRECTION
CALIBRATION

期刊

Optics Letters 封面图
Optics Letters
IF:
3.3
论文数:
4.0W
被引数:
7.6W

机构

T
tsinghua university
学者数:
11.9W
论文数: 10.0W
被引数: 137
引用论文

引用论文

Noise-tolerant wavefront shaping in a Hadamard basis
err2021-05-21
err19
errOAAI
errMastiani, Bahareh; Vellekoop, Ivo M.
err分享
err收藏
Neonatal surgical outcomes: a prospective observational study at a Tertiary Academic Hospital in Johannesburg, South Africa
err2021-03-19
err0
PREAI
errA. Withers; K. Cronin; M. Mabaso; G. Brisighelli; T. Gabler; D. Harrison; N. Patel; C. Westgarth-Taylor; J. Loveland
err分享
err收藏
Phase I/II, open-label, multiple ascending dose trial of AGEN2034, an anti–PD-1 monoclonal antibody, in advanced solid malignancies: Results of dose escalation in advanced cancer and expansion cohorts in subjects with relapsed/refractory cervical cancer
err2018-10-01
err0
errOAAI
errC. Drescher; K.N. Moore; J.F. Liu; D.M. O’Malley; E.W. Wang; J.S.-Z. Wang; V. Subbiah; B.A. Wilky; G. Yuan; C.D. Dupont; A.M. Gonzalez; D. Savitsky; S. Coulter; O. Shebanova; E. Dow; W. Ortuzar; J.S. Buell; R.B. Stein; H. Youssoufian
err分享
err收藏
err分享
err收藏
学者 查看更多内容